What Optellum and Coreline Soft Announced About Their Lung Cancer Collaboration

Optellum said on 13 August 2026 that it and Coreline Soft had announced an intent to collaborate, under which Optellum would integrate Coreline Soft AVIEW Lung Nodule CAD into LungOS, the Optellum platform for thoracic care. Optellum describes the Coreline Soft product as FDA cleared computer aided detection software designed to assist radiologists in detecting lung nodules, and presents the combination as connecting detection with risk assessment and care management in one workflow. Johnathan Watkins, chief executive of Optellum, is quoted calling it highly complementary to what he describes as the company position in reimbursed nodule risk assessment and management, and Jin Kook Kim, chief executive of Coreline Soft, is quoted on contributing to a more connected and scalable lung cancer care model. The announcement states an intent rather than a completed integration, and names no timetable, no financial terms and no customer.

Why the Optellum and Coreline Soft Lung Pathway Deal Matters to Radiology Leaders

This is two companies admitting they each own half of a job. Detection software tells you a nodule is there; risk software tells you how worried to be. A hospital buying them separately pays twice, integrates twice and ends up with two tools that may disagree, which is a bad position when the disagreement concerns cancer. Joining them is the obvious fix and it is genuinely useful if it happens. The words to hold onto are intent to collaborate. That is not a signed integration, not a product and not a date, and announcements at this stage sometimes go no further. Two more things stay open. Neither company has said what a hospital would pay for the combined product, and nobody has said what happens when the detection tool and the risk tool point in different directions. That handling rule is the part a radiology lead should ask about first.

Where the Optellum Update Comes From

Optellum is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Optellum original source.

How We Would Research the Optellum and Coreline Soft Collaboration

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would start by asking both companies whether the integration has shipped, because an intent to collaborate and a released product are a long way apart.
  2. Then we would read each product regulatory record separately, since detection and risk scoring are cleared as different things and a combined workflow does not inherit a combined permission.
  3. We would ask what a radiologist is told to do when the detection tool and the risk score disagree, because that rule decides whether the combination helps or adds doubt.